2021
DOI: 10.1016/j.bbrc.2021.08.066
|View full text |Cite
|
Sign up to set email alerts
|

Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1–40) and (1–42) in plasma samples

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
14
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 17 publications
(15 citation statements)
references
References 29 publications
1
14
0
Order By: Relevance
“…Usually, immunoassays have difficulties in demonstrating sufficient specificity, particularly for the measurement of proteins that have several types of fragments, such as Aβ, because the specificity of the immunoassay depends on the specificity of the antibodies. We confirmed the specificity of our immunoassays by evaluating their correlation with IP-MS assays [ 27 ] and found that our assay accurately measured the Aβ42 and Aβ40 levels in plasma. The findings provide proof of principle that our immune-based plasma Aβ42/Aβ40 assay accurately distinguishes brain Aβ-positive from Aβ-negative individuals, as determined by visual reads of amyloid PET, with AUCs of 0.941 and 0.868 in the discovery and validation studies, respectively.…”
Section: Discussionsupporting
confidence: 61%
See 2 more Smart Citations
“…Usually, immunoassays have difficulties in demonstrating sufficient specificity, particularly for the measurement of proteins that have several types of fragments, such as Aβ, because the specificity of the immunoassay depends on the specificity of the antibodies. We confirmed the specificity of our immunoassays by evaluating their correlation with IP-MS assays [ 27 ] and found that our assay accurately measured the Aβ42 and Aβ40 levels in plasma. The findings provide proof of principle that our immune-based plasma Aβ42/Aβ40 assay accurately distinguishes brain Aβ-positive from Aβ-negative individuals, as determined by visual reads of amyloid PET, with AUCs of 0.941 and 0.868 in the discovery and validation studies, respectively.…”
Section: Discussionsupporting
confidence: 61%
“…The Aβ assays required 30 μL of plasma, and measurements were completed within 17 min per assay. These assay procedures have been previously described [ 27 ].…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, other studies demonstrated the potential of plasma Aβ markers in capturing early cerebral Aβ changes [ 10 , 22 , 23 ]. With the development of technology, recent studies have revealed that mass spectrometry-based methods outperform most immunoassays in the precise assays of plasma Aβ [ 44 46 ]. We thus hypothesize that the lack of significant changes in plasma Aβ levels may be an artifact attributable to the technique employed.…”
Section: Discussionmentioning
confidence: 99%
“…21,22 Based on the specific properties of QuantiFluor, some biosensors have been developed using the interaction of the dye and free DNA aptamers not bound with a target marker using fluorescence detection. 21 In this research, we developed for the first time an aptasensor with chemiluminescence detection for the early diagnosis of Alzheimer's disease using a cost-effective DNA aptamer of beta-amyloid peptide 1-40, instead of expensive and intractable antibodies, 23,24 and Chamel Green based on two hypotheses. First, Chamel Green electrostatically bound with free DNA aptamers emits bright chemiluminescence if the high-energy intermediate formed from the reaction between guanines of the free DNA aptamer and a phenylglyoxal hydrate derivative, as shown in Scheme 1(A), can transfer energy to Chamel Green intercalated with the DNA aptamer based on internal-CRET instead of conventional intra-CRET as shown in Scheme 1(B).…”
Section: Introductionmentioning
confidence: 99%